Department of Internal Medicine-Nephrology, Leiden University Medical Center, Leiden, Netherlands.
Department of Cell and Chemical Biology, Leiden University Medical Center, Leiden, Netherlands.
Front Immunol. 2023 Jan 12;13:1058763. doi: 10.3389/fimmu.2022.1058763. eCollection 2022.
End stage renal disease is an increasing problem worldwide driven by aging of the population and increased prevalence of metabolic disorders and cardiovascular disease. Currently, kidney transplantation is the only curative option, but donor organ shortages greatly limit its application. Regenerative medicine has the potential to solve the shortage by using stem cells to grow the desired tissues, like kidney tissue. Immune rejection poses a great threat towards the implementation of stem cell derived tissues and various strategies have been explored to limit the immune response towards these tissues. However, these studies are limited by targeting mainly T cell mediated immune rejection while the rejection process also involves innate and humoral immunity. In this study we investigate whether inhibition of the complement system in human induced pluripotent stem cells (iPSC) could provide protection from such immune injury. To this end we created knock-in iPSC lines of the membrane bound complement inhibitor CD55 to create a transplant-specific protection towards complement activation. CD55 inhibits the central driver of the complement cascade, C3 convertase, and we show that overexpression is able to decrease complement activation on both iPSCs as well as differentiated kidney organoids upon stimulation with anti-HLA antibodies to mimic the mechanism of humoral rejection.
终末期肾病是一个全球性的日益严重的问题,其原因是人口老龄化以及代谢紊乱和心血管疾病的患病率增加。目前,肾移植是唯一的治愈方法,但供体器官短缺极大地限制了其应用。再生医学有可能通过使用干细胞来生长所需的组织,如肾组织,来解决短缺问题。免疫排斥对干细胞衍生组织的实施构成了巨大威胁,因此已经探索了各种策略来限制对这些组织的免疫反应。然而,这些研究主要针对 T 细胞介导的免疫排斥,而排斥过程还涉及固有免疫和体液免疫。在这项研究中,我们研究了抑制人类诱导多能干细胞(iPSC)中的补体系统是否可以提供对这种免疫损伤的保护。为此,我们创建了膜结合补体抑制剂 CD55 的基因敲入 iPSC 系,以创造针对补体激活的移植特异性保护。CD55 抑制补体级联反应的中心驱动因子 C3 转化酶,我们表明,在受到模拟体液排斥机制的抗 HLA 抗体刺激时,过表达能够降低 iPSC 以及分化的肾类器官上的补体激活。